Evidence map›Paper›PMID 40419486›Full record

ArticleNature communications2025

High-speed atomic force microscopy and 3D modeling reveal the structural dynamics of ADAR1 complexes.

Madhu Biyani, Yasuhiro Isogai, Kirti Sharma, Shoei Maeda, Hinako Akashi, Yui Sugai, Masataka Nakano, Noriyuki Kodera, Manish Biyani, Miki Nakajima

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Madhu BiyaniNano Life Science Institute (WPI-NanoLSI), Kanazawa University, Kanazawa, Japan. biyani@staff.kanazawa-u.ac.jp.ORCID http://orcid.org/0009-0003-1750-3501
Yasuhiro IsogaiDepartment of Pharmaceutical Engineering, Faculty of Engineering, Toyama Prefectural University, Toyama, Japan.
Kirti SharmaNano Life Science Institute (WPI-NanoLSI), Kanazawa University, Kanazawa, Japan.
Shoei MaedaDrug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan.
Hinako AkashiDrug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan.
Yui SugaiDrug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan.
Masataka NakanoNano Life Science Institute (WPI-NanoLSI), Kanazawa University, Kanazawa, Japan.
Noriyuki KoderaNano Life Science Institute (WPI-NanoLSI), Kanazawa University, Kanazawa, Japan.ORCID http://orcid.org/0000-0003-4880-8423
Manish BiyaniBioSeeds Corporation, Ishikawa Create Labo, Nomi City, Ishikawa, Japan. biyani@kwansei.ac.jp.ORCID http://orcid.org/0000-0001-8761-7107
Miki NakajimaNano Life Science Institute (WPI-NanoLSI), Kanazawa University, Kanazawa, Japan.

Funding

MEXT | Japan Society for the Promotion of Science (JSPS) 23K06067
6 · The paper itself

Abstract

Targeting abnormal dysregulation of adenosine-to-inosine deamination by ADAR enzymes offers a promising therapeutic strategy in cancer research. However, the development of effective inhibitors is impeded by the incomplete structural information on ADAR1 complexes. In this study, we employ a combination of computational 3D modeling and high-speed atomic force microscopy to elucidate the atomic and molecular dynamics of ADAR1. Two distinct interface regions (IFx and IFy) on the surface of the deaminase domain and oligomerization structural models are identified. Single-molecule-level insights into the structural dynamics of ADAR1 reveal the oligomerization of ADAR1 monomers through the self-assembly of deaminase domains. In the presence of the substrate dsRNA, the N-terminal region, including RNA-binding domains, of ADAR1 dimer exhibits a controlled flexible conformation and promotes a stable dimeric interaction with dsRNA for RNA editing. These findings provide the basis for the development of targeted inhibitors to regulate ADAR1 activity in therapeutic applications.

Indexed as

Adenosine DeaminaseMicroscopy, Atomic ForceRNA-Binding ProteinsHumansModels, MolecularMolecular Dynamics SimulationProtein BindingProtein DomainsProtein MultimerizationRNA, Double-StrandedRNA EditingADAR protein, humanAdenosine DeaminaseRNA-Binding ProteinsRNA, Double-Stranded

Identifiers

PMID40419486
PMCPMC12106642

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.